Staff Reports
It’s been almost two years since the Supreme Court wisely gave power back to the states regarding abortion decisions, and now they are gearing up to tackle a case that could put restrictions on a popular abortion pill. The FDA, in a questionable move back in 2016, decided to make it easier to get your hands on mifepristone, one of the most commonly used drugs in medication abortions.
Biden vows to forge ahead with student loan handouts, has 4 words for all his critics https://t.co/CyPE0tklkQ
— Fox News (@FoxNews) March 25, 2024
Of course, a group of medical associations that value life and oppose abortion have stepped up to challenge the FDA’s actions, claiming that the regulations around mifepristone have been recklessly relaxed. Before even diving into the legality of the changes the FDA made, the Supreme Court has to figure out if these doctors even have a right to be sticking their stethoscopes into this fight.
If the Supreme Court leans towards reversing the FDA’s leniency, it could have a massive impact on how accessible this abortion pill is across the country. Whether you live in a state that respects life or one that doesn’t, this decision could make a big difference in the availability of this controversial pill.
Mifepristone, a real superstar in the abortion pill world, has been responsible for over half of the abortions in the U.S. Hey, Guttmacher Institute, that sure sounds like a lot of abortions for a so-called “women’s health” drug. The FDA’s cozying up to this pill, like letting it be sent through the mail and cutting down on pesky in-person visits, has definitely led to more people choosing this route for their abortions.
But wait, the Supreme Court is now rolling up its sleeves to question the FDA’s decisions. They’re sniffing around the FDA’s moves from 2016 that broadened the horizons for mifepristone, letting it be used for longer pregnancies and reducing how often you actually have to see a doctor in person for it. Sounds fishy, right?
This whole shebang landed at the Supreme Court’s doorstep courtesy of medical groups that are all about saving lives and not ending them. They’re not fans of the FDA giving nods of approval to mifepristone, and they’re certainly not happy about the FDA essentially putting this abortion pill on the fast track without proper oversight.
Come June, we’ll hear the final word from the Supreme Court on this hot-button issue. Brace yourselves, folks. The abortion debate is heating up, and this decision could send shockwaves through the nation’s abortion landscape.
